|
FY2026
12 months to Jul 31, 2026
|
FY2025
12 months to Jul 31, 2025
|
FY2024
12 months to Jul 31, 2024
|
FY2023
12 months to Jul 31, 2023
|
FY2022
12 months to Jul 31, 2022
|
|
|---|---|---|---|---|---|
| Cash Flows from Operating Activities | |||||
| Net Income | |||||
| Adjustments to reconcile net income to net cash provided by operating activites: | |||||
| Depreciation and amortization | |||||
| Non-cash stock compensation expense | |||||
| Loss on pension termination | |||||
| Deferred income tax expense | |||||
| Net increase (decrease) to provision for bad debts and cash discounts | |||||
| Loss on impairment of patent applications | |||||
| Accretion for asset retirement obligation | |||||
| Gain from release of asset retirement obligation | |||||
| Loss (gain) on disposal of property, plant and equipment | |||||
| (Increase) decrease in: | |||||
| Accounts receivable | |||||
| Inventories | |||||
| Prepaid expenses | |||||
| Deferred income tax, net | |||||
| Other assets | |||||
| Increase (decrease) in: | |||||
| Accounts payable | |||||
| Accrued expenses | |||||
| Deferred compensation | |||||
| Other liabilities | |||||
| Total Adjustments | |||||
| Net Cash Provided by Operating Activities | |||||
| Cash Flows from Investing Activities | |||||
| Capital expenditures | |||||
| Proceeds from sale of property, plant and equipment | |||||
| Acquisition of business | |||||
| Acquisition of equity in Agromex | |||||
| Other investing activities | |||||
| Net Cash Used in Investing Activities | |||||
| Cash Flows from Financing Activities | |||||
| Proceeds from issuance of notes payable | |||||
| Principal payments on notes payable | |||||
| Payment of debt issuance costs | |||||
| Dividends paid | |||||
| Purchase of treasury stock | |||||
| Net Cash (Used in) Provided by Financing Activities | |||||
| Effect of exchange rate changes on cash and cash equivalents | |||||
| Net Increase (Decrease) in Cash and Cash Equivalents | |||||
| Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Beginning Balance | |||||
| Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Ending Balance | |||||
| Cash and cash equivalents | |||||
| Restricted Cash | |||||
| Restricted cash in prepaid expenses and other assets | |||||
| (Decrease) increase to restricted cash | |||||
| Final settlement of acquisition of Ultra Pet | |||||
| Additional Cash Flow Elements and Supplemental Cash Flow Information | |||||
| Interest payments, net of amounts capitalized | |||||
| Income tax payments | |||||
| Right-of-use assets obtained in exchange for new operating lease liabilities | |||||
| Capital expenditures accrued, but not paid | |||||
| Noncash Investing and Financing Items | |||||
| Change in capital expenditures in accounts payable | |||||
| Change in capital expenditures in accrued expenses | |||||
| Cash dividends declared and accrued, but not paid | |||||
| Increase in reclamation asset and liability | |||||
Loading...